AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30056104 — intervention group
Group type: EXPERIMENTAL
Intervention: No or light alcohol consumption (component of AHEI-2010)
Number of subjects: 459
Study 27622897 — intervention group
Group type: EXPERIMENTAL
Intervention: DA alginate antacid
Number of subjects: 44
Study 27622897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 24521295 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflectance confocal microscopy (RCM)
Number of subjects: 48
Study 24521295 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized skin surface biopsy (SSSB)
Number of subjects: 48
Study 24521295 — intervention group
Group type: EXPERIMENTAL
Intervention: RCM
Number of subjects: 48
Study 24521295 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 48
Study 24521295 — intervention group
Group type: EXPERIMENTAL
Intervention: RCM vs SSSB
Number of subjects: 48
Study 23110157 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback pamphlet
Number of subjects: 1767
Study 23110157 — intervention group
Group type: COMPARATOR
Intervention: Control pamphlet
Number of subjects: 1767
Study 23110157 — intervention group
Group type: COMPARATOR
Intervention: No intervention control
Number of subjects: 1767
Study 20329658 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg (test product)
Number of subjects: 74
Study 20329658 — intervention group
Group type: COMPARATOR
Intervention: Exemestane 25 mg (reference product)
Number of subjects: 74
Study 18446589 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 80/4.5 microg x 2 inhalations (160/9 microg)
Number of subjects: 0
Study 18446589 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone/salmeterol DPI 250/50 microg x 1 inhalation
Number of subjects: 0
Study 18446589 — intervention group
Group type: COMPARATOR
Intervention: Albuterol pMDI 90 microg x 2 inhalations (180 microg)
Number of subjects: 0
Study 18446589 — intervention group
Group type: COMPARATOR
Intervention: Placebo pMDI
Number of subjects: 0
Study 16386890 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (CHART)
Number of subjects: 402
Study 16386890 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 402
Study 16386890 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 402
Study 12793220 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Professional Whitestrips (6.5% H2O2)
Number of subjects: 90
Study 12793220 — intervention group
Group type: EXPERIMENTAL
Intervention: Day White 2 (7.5% H2O2)
Number of subjects: 90
Study 12793220 — intervention group
Group type: EXPERIMENTAL
Intervention: Nite White Excel 2 (16% carbamide peroxide equivalent)
Number of subjects: 90
Study 10889800 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions causing negative energy balance (specific interventions not detailed)
Number of subjects: 0
Study 10889800 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss as a treatment
Number of subjects: 0
Study 10889800 — intervention group
Group type: COMPARATOR
Intervention: RCT design
Number of subjects: 0
Study 10889800 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-sample studies with regression analysis
Number of subjects: 0
Study 10889800 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical practice treatments
Number of subjects: 0
Study 8783687 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 rejection treatment
Number of subjects: 15
Study 8783687 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 rejection treatments
Number of subjects: 15
Study 8783687 — intervention group
Group type: EXPERIMENTAL
Intervention: >= 3 rejection treatments
Number of subjects: 15
Study 8783687 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pretransplantation CMV serology
Number of subjects: 15
Study 8783687 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipient-negative and donor-positive pretransplantation CMV serology
Number of subjects: 15
Study 8783687 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV infection
Number of subjects: 15
Study 1731541 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms/mL buprenorphine with 0.015% bupivacaine and 1 microgram/mL epinephrine
Number of subjects: 78
Study 1731541 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms/mL fentanyl with 0.015% bupivacaine and 1 microgram/mL epinephrine
Number of subjects: 78
Study 1731541 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms/mL fentanyl with 0.015% bupivacaine
Number of subjects: 78
Study 6475749 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Rose Questionnaire for myocardial infarction
Number of subjects: 0
Study 6475749 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive clinical history of myocardial infarction
Number of subjects: 0
Study 6475749 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive ECG for myocardial infarction
Number of subjects: 0
Study 6475749 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline prevalence of angina pectoris
Number of subjects: 0
Study 6475749 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose Questionnaire evidence of myocardial infarction
Number of subjects: 0
Study 6475749 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year incidence of myocardial infarction, positive ECG or history, or positive Rose Questionnaire
Number of subjects: 0
Study 30673028 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus 3 watts gaseous ozone in two separate applications five days apart
Number of subjects: 40
Study 30673028 — intervention group
Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 40
Study 30442354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical thrust manipulation
Number of subjects: 54
Study 26423396 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely monitored (RM) pacemakers
Number of subjects: 76
Study 26423396 — intervention group
Group type: COMPARATOR
Intervention: Hospital-monitored (HM) pacemakers
Number of subjects: 76
Study 25205062 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-0 V-Loc
Number of subjects: 40
Study 25205062 — intervention group
Group type: COMPARATOR
Intervention: 3-0 Stratafix
Number of subjects: 40
Study 22188239 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention (PFI)
Number of subjects: 147
Study 22188239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention (CBI)
Number of subjects: 147
Study 22188239 — intervention group
Group type: COMPARATOR
Intervention: Assessment-Only Control (AOC)
Number of subjects: 147
Study 19996349 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled mannitol alone
Number of subjects: 38
Study 19996349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised rhDNase alone
Number of subjects: 38
Study 19996349 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mannitol and rhDNase
Number of subjects: 38
Study 17645262 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture plus epidural analgesia
Number of subjects: 60
Study 17645262 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 60
Study 16083518 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan orally disintegrating tablet (ODT)
Number of subjects: 0
Study 16083518 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan ODT
Number of subjects: 0
Study 16083518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11788558 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human IL-10 (20 microg/kg) in patients with CACD
Number of subjects: 126
Study 11788558 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human IL-10 (20 microg/kg) in patients with MCD
Number of subjects: 126
Study 11788558 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with CACD
Number of subjects: 126
Study 11788558 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with MCD
Number of subjects: 126
Study 9797592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cows' milk protein (n = 758)
Number of subjects: 1533
Study 9797592 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 775)
Number of subjects: 1533
Study 7665750 — intervention group
Group type: EXPERIMENTAL
Intervention: Least squares fitting (LSF) method during pressure support ventilation (PSV)
Number of subjects: 11
Study 7665750 — intervention group
Group type: EXPERIMENTAL
Intervention: Least squares fitting (LSF) method at increased pressure support levels
Number of subjects: 11
Study 7665750 — intervention group
Group type: EXPERIMENTAL
Intervention: Least squares fitting (LSF) method in controlled mechanical ventilation (CMV)
Number of subjects: 11
Study 2576246 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride (morning dosage)
Number of subjects: 6
Study 2576246 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride (evening dosage)
Number of subjects: 6
Study 2576246 — intervention group
Group type: COMPARATOR
Intervention: Placebo (morning and evening)
Number of subjects: 6
Study 551922 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific hypotensive therapy
Number of subjects: 3
Study 551922 — intervention group
Group type: EXPERIMENTAL
Intervention: No specific treatment
Number of subjects: 3
Study 551922 — intervention group
Group type: COMPARATOR
Intervention: Hospital sample
Number of subjects: 3
Study 31520543 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges
Number of subjects: 39
Study 31520543 — intervention group
Group type: COMPARATOR
Intervention: Control lozenges
Number of subjects: 39
Study 30204517 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein protein (CP) 40 g presleep
Number of subjects: 10
Study 30204517 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) 40 g carbohydrates presleep
Number of subjects: 10
Study 28885372 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (10,000 lux; active condition)
Number of subjects: 0
Study 28885372 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (<300 lux; control condition)
Number of subjects: 0
Study 26083409 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutritional supplement with additional vitamins and minerals
Number of subjects: 181
Study 26083409 — intervention group
Group type: COMPARATOR
Intervention: Control group (Lipid-based nutritional supplement without additional vitamins and minerals)
Number of subjects: 181
Study 26083409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 181
Study 22843632 — intervention group
Group type: EXPERIMENTAL
Intervention: UV photo intervention
Number of subjects: 0
Study 22843632 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 0
Study 22843632 — intervention group
Group type: COMPARATOR
Intervention: No UV photo
Number of subjects: 0
Study 22843632 — intervention group
Group type: COMPARATOR
Intervention: No MI
Number of subjects: 0
Study 21770996 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP with azithromycin (AZM) 500 mg/day for 5 days
Number of subjects: 40
Study 21770996 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 40
Study 19293261 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (5 or 10 g/d) plus GH (0, 3, or 5 microg/kg . d) for 16 weeks
Number of subjects: 122
Study 16686554 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine and whey protein supplementation (SUPP)
Number of subjects: 33
Study 16686554 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate placebo (PL)
Number of subjects: 33
Study 16686554 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 33
Study 12918546 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 12918546 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0
Study 12918546 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial-synchronised biventricular pacing
Number of subjects: 0
Study 12918546 — intervention group
Group type: COMPARATOR
Intervention: Valsartan with ACE inhibitor and beta-blocker
Number of subjects: 0
Study 11015817 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 227
Study 11015817 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic medications
Number of subjects: 227
Study 8784894 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional treatment planning
Number of subjects: 15
Study 8784894 — intervention group
Group type: COMPARATOR
Intervention: Spared glands
Number of subjects: 15
Study 1294196 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal imagery
Number of subjects: 30
Study 1294196 — intervention group
Group type: EXPERIMENTAL
Intervention: External imagery
Number of subjects: 30
Study 1294196 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual exercise
Number of subjects: 30
Study 1294196 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal imagery and External imagery
Number of subjects: 30
Study 6738652 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (mean plasma level, 13 +/- 2 mg per liter) after 7 days
Number of subjects: 15
Study 6738652 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline after 30 days
Number of subjects: 15
Study 6738652 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 15
Study 6738652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30539303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 86
Study 30539303 — intervention group
Group type: COMPARATOR
Intervention: Non-tourniquet
Number of subjects: 86
Study 31162568 — intervention group
Group type: EXPERIMENTAL
Intervention: Neladenoson 5 mg
Number of subjects: 305
Study 31162568 — intervention group
Group type: EXPERIMENTAL
Intervention: Neladenoson 10 mg
Number of subjects: 305
Study 31162568 — intervention group
Group type: EXPERIMENTAL
Intervention: Neladenoson 20 mg
Number of subjects: 305
Study 31162568 — intervention group
Group type: EXPERIMENTAL
Intervention: Neladenoson 30 mg
Number of subjects: 305
Study 31162568 — intervention group
Group type: EXPERIMENTAL
Intervention: Neladenoson 40 mg
Number of subjects: 305
Study 31162568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 28629329 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aids (DA)
Number of subjects: 816
Study 28629329 — intervention group
Group type: COMPARATOR
Intervention: Standard brochure
Number of subjects: 816
Study 26049794 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute rest interval (1RI)
Number of subjects: 22
Study 26049794 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute rest interval (2RI)
Number of subjects: 22
Study 26049794 — intervention group
Group type: EXPERIMENTAL
Intervention: 1RI
Number of subjects: 22
Study 26049794 — intervention group
Group type: EXPERIMENTAL
Intervention: 2RI
Number of subjects: 22
Study 24483103 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐formulated decoctions for activating blood nourishing blood (ABNB), activating blood removing stasis (ABRS), and activating blood softening hard mass (ABSHM)
Number of subjects: 100
Study 24483103 — intervention group
Group type: COMPARATOR
Intervention: Compound Biejia Ruangan Tablet (CBRT)
Number of subjects: 100
Study 21593464 — intervention group
Group type: EXPERIMENTAL
Intervention: Steri-Strips patching
Number of subjects: 87
Study 21593464 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper patching
Number of subjects: 87
Study 21593464 — intervention group
Group type: COMPARATOR
Intervention: Conservative observation
Number of subjects: 87
Study 19231318 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine‐atropine stress echocardiography (DASE)
Number of subjects: 290
Study 19231318 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram exercise testing (EET)
Number of subjects: 290
Study 19231318 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 290
Study 16534704 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented Cone stem
Number of subjects: 45
Study 16534704 — intervention group
Group type: COMPARATOR
Intervention: Cemented Bimetric stem
Number of subjects: 45
Study 16534704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone stems (follow-up study)
Number of subjects: 45
Study 12495964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough frequency measured using an ambulatory cough meter
Number of subjects: 40
Study 12495964 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 (concentration of capsaicin causing two coughs)
Number of subjects: 40
Study 12495964 — intervention group
Group type: EXPERIMENTAL
Intervention: C5 (concentration of capsaicin causing five or more coughs)
Number of subjects: 40
Study 12495964 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective cough scores (parent and child recorded)
Number of subjects: 40
Study 11731752 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant ventilation (group AA) during clamping
Number of subjects: 25
Study 11731752 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ventilation to preserve normocapnia (group AB) during clamping
Number of subjects: 25
Study 11731752 — intervention group
Group type: COMPARATOR
Intervention: Constant ventilation (group OD) in occlusive patients
Number of subjects: 25
Study 9415794 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief clinician advice (30 seconds), a 15‐minute motivational session by counselors, and printed materials
Number of subjects: 516
Study 8352668 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 30
Study 8352668 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30
Study 8352668 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 30
Study 3675128 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental information on how to do the Wisconsin Card Sorting Test, including explicit card-by-card instruction.
Number of subjects: 3
Study 3675128 — intervention group
Group type: COMPARATOR
Intervention: Control group (no incremental information provided).
Number of subjects: 3
Study 29791681 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational dance program for seven months
Number of subjects: 85
Study 29791681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational dance)
Number of subjects: 85
Study 26704742 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention before the second scenario
Number of subjects: 33
Study 26704742 — intervention group
Group type: COMPARATOR
Intervention: Control group (performed both scenarios before receiving the intervention)
Number of subjects: 33
Study 24189463 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg/day
Number of subjects: 50
Study 24189463 — intervention group
Group type: COMPARATOR
Intervention: Control group (other anti-hypertensive drugs)
Number of subjects: 50
Study 23246868 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly absorbable polypropylene-polyglactin mesh (Vypro II)
Number of subjects: 312
Study 23246868 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight polypropylene mesh (Premilene Mesh LP)
Number of subjects: 312
Study 23246868 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional densely woven polypropylene mesh (Premilene)
Number of subjects: 312
Study 21941778 — intervention group
Group type: EXPERIMENTAL
Intervention: HP
Number of subjects: 91
Study 21941778 — intervention group
Group type: COMPARATOR
Intervention: HP-CVVH
Number of subjects: 91
Study 17614245 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 677
Study 17614245 — intervention group
Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 677
Study 17070177 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 496
Study 17070177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study 12587969 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training and education (Exercise group)
Number of subjects: 66
Study 12587969 — intervention group
Group type: COMPARATOR
Intervention: Education alone (Control group)
Number of subjects: 66
Study 11113218 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA treatment within 0 to 90 minutes
Number of subjects: 0
Study 11113218 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA treatment within 91 to 180 minutes
Number of subjects: 0
Study 11113218 — intervention group
Group type: COMPARATOR
Intervention: Control group (treated after 90 minutes)
Number of subjects: 0
Study 11113218 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA treatment
Number of subjects: 0
Study 9419073 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects approaching from the right
Number of subjects: 0
Study 9419073 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects approaching at different velocities and directions
Number of subjects: 0
Study 9419073 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal coordination between transport and grasp components
Number of subjects: 0
Study 8402803 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotene toothpaste (LPO system)
Number of subjects: 26
Study 8402803 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste (Vademecum, no LPO system)
Number of subjects: 26
Study 3324838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular premedication with 0.12 mg.kg‐1 midazolam and 0.5 mg atropine
Number of subjects: 24
Study 3324838 — intervention group
Group type: COMPARATOR
Intervention: Atropine only (control group)
Number of subjects: 24
Study 28903582 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone treatment group
Number of subjects: 219
Study 28903582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glucocorticoid treatment)
Number of subjects: 219
Study 27863807 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol plus methotrexate
Number of subjects: 915
Study 27863807 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab plus methotrexate
Number of subjects: 915
Study 27863807 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to certolizumab pegol after non-response to adalimumab
Number of subjects: 915